Region of interest localization, tissue storage time, and antibody binding density-a technical note on the GeoMx® Digital Spatial Profiler [0.03%]
感兴趣区域定位、组织储存时间和抗体结合密度——关于GeoMx® 数字空间剖析器的技术说明
S Böning,F Schneider,A-K Huber et al.
S Böning et al.
Background: Spatial biology is an emerging concept to interrogate tumor heterogeneity. The NanoString GeoMx® Digital Spatial Profiling (DSP) platform has become increasingly available. It combines high-plex analysis of p...
A novel anti-FGFR1 monoclonal antibody OM-RCA-01 exhibits potent antitumor activity and enhances the efficacy of immune checkpoint inhibitors in lung cancer models [0.03%]
一种新型抗FGFR1单克隆抗体OM-RCA-01在肺癌模型中表现出强大的抗肿瘤活性并增强免疫检查点抑制剂的疗效
I Tsimafeyeu,P Makhov,D Ovcharenko et al.
I Tsimafeyeu et al.
Background: Fibroblast growth factor receptor 1 (FGFR1) plays a crucial role in carcinogenesis. Exploring the combination of the novel humanized monoclonal anti-FGFR1 antibody OM-RCA-01 and immunotherapy was intriguing du...
An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy [0.03%]
一种用于基于Vγ9Vδ2-T细胞免疫治疗的体外检测的人皮肤黑色素瘤器官型模型
E Michielon,L A King,T Waaijman et al.
E Michielon et al.
Background: Despite considerable advancements in cancer immunotherapy, advanced melanoma still presents a substantial clinical challenge. In an effort to explore treatment options, we examined the immunotherapeutic potent...
Integrated noninvasive diagnostics for prediction of survival in immunotherapy [0.03%]
免疫治疗生存预测的集成无创诊断方法
M Yeghaian,Z Bodalal,T M Tareco Bucho et al.
M Yeghaian et al.
Background: Integrating complementary diagnostic data sources promises enhanced robustness in the predictive performance of artificial intelligence (AI) models, a crucial requirement for future clinical validation/impleme...
I Olivera,I Etxeberria,C Luri-Rey et al.
I Olivera et al.
Adoptive T-cell therapies (ACTs) including tumor-infiltrating lymphocytes and engineered T cells (transgenic T-cell receptor and chimeric antigen receptor T cells), have made an important impact in the field of cancer treatment over the pas...
Tumor-infiltrating lymphocytes and immune-related adverse events in advanced melanoma [0.03%]
肿瘤浸润淋巴细胞与晚期黑色素瘤患者的免疫相关不良事件的关系研究
I A J van Duin,M Schuiveling,L S Ter Maat et al.
I A J van Duin et al.
Background: The predictive value of tumor-infiltrating lymphocytes (TILs) in immune-related adverse event (irAE) development remains unknown, although an association between tumor immunogenicity and irAEs has been suggest...
Effect of glucocorticoids for the management of immune-related adverse events on outcome in melanoma patients treated with immunotherapy-a retrospective and biomarker study [0.03%]
糖皮质激素对免疫治疗的黑色素瘤患者出现免疫相关不良事件的影响及生物标志物研究回顾性分析
F Costa Svedman,M Liapi,A Månsson-Broberg et al.
F Costa Svedman et al.
Background: Immune-related adverse events (IRAEs) during therapy with immune checkpoint inhibitors (ICIs) are common, and their management sometimes requires glucocorticoids (GCs). Predictors for development of IRAEs and ...
Immune biomarker evaluation of sequential tyrosine kinase inhibitor and nivolumab monotherapies in renal cell carcinoma: the phase I TRIBE trial [0.03%]
一项I期临床试验：肾细胞癌序贯靶向免疫单药治疗的生物标志物评估(TRIBE试验)
K S Shohdy,M Pillai,K S Abbas et al.
K S Shohdy et al.
Background: Predictive biomarkers for immune checkpoint blockade in the second-line treatment of metastatic renal cell carcinoma (mRCC) are lacking. Mater...
Biomaterials-mediated ligation of immune cell surface receptors for immunoengineering [0.03%]
生物材料介导的免疫细胞表面受体连接用于免疫工程
H Cui,L Zhang,Y Shi
H Cui
A wide variety of cell surface receptors found on immune cells are essential to the body's immunological defense mechanisms. Cell surface receptors enable immune cells to sense extracellular stimuli and identify pathogens, transmitting acti...
Updates in the pathogenesis and management of immune-related enterocolitis, hepatitis and cardiovascular toxicities [0.03%]
免疫相关性肠炎、肝炎和心血管毒性的发病机制及管理进展
J McKenzie,E Sneath,A Trinh et al.
J McKenzie et al.
Immune checkpoint inhibitors (ICIs) have become a cornerstone of treatment for many solid organ malignancies. Alongside increasing use, the occurrence of immune-related adverse events (irAEs) has also increased and remains a significant cha...